<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id><journal-title-group><journal-title>BMC Cancer</journal-title></journal-title-group><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25424120</article-id><article-id pub-id-type="pmc">4289339</article-id><article-id pub-id-type="publisher-id">5129</article-id><article-id pub-id-type="doi">10.1186/1471-2407-14-883</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Seung Tae</given-names></name><address><email>seungtae1.kim@samsung.com</email></address><xref ref-type="aff" rid="Aff85"/></contrib><contrib contrib-type="author"><name><surname>Hong</surname><given-names>Yong Sang</given-names></name><address><email>yshong@amc.seoul.kr</email></address><xref ref-type="aff" rid="Aff86"/></contrib><contrib contrib-type="author"><name><surname>Lim</surname><given-names>Ho Yeong</given-names></name><address><email>hoylim@skku.edu</email></address><xref ref-type="aff" rid="Aff85"/></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Jeeyun</given-names></name><address><email>jyunlee@skku.edu</email></address><xref ref-type="aff" rid="Aff85"/></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Tae Won</given-names></name><address><email>twkimmd@amc.seoul.kr</email></address><xref ref-type="aff" rid="Aff86"/></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Kyu-Pyo</given-names></name><address><email>kkp1122@gmail.com</email></address><xref ref-type="aff" rid="Aff86"/></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Sun Young</given-names></name><address><email>sykim@ncc.re.kr</email></address><xref ref-type="aff" rid="Aff87"/></contrib><contrib contrib-type="author"><name><surname>Baek</surname><given-names>Ji Yeon</given-names></name><address><email>jbaek@ncc.re.kr</email></address><xref ref-type="aff" rid="Aff87"/></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Jee Hyun</given-names></name><address><email>jhkimmd@snu.ac.kr</email></address><xref ref-type="aff" rid="Aff88"/></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Keun-Wook</given-names></name><address><email>hmodoctor@hanmail.net</email></address><xref ref-type="aff" rid="Aff88"/></contrib><contrib contrib-type="author"><name><surname>Chung</surname><given-names>Ik-Joo</given-names></name><address><email>ijchung@jnu.ac.kr</email></address><xref ref-type="aff" rid="Aff89"/></contrib><contrib contrib-type="author"><name><surname>Cho</surname><given-names>Sang-Hee</given-names></name><address><email>sh115@chollian.net</email></address><xref ref-type="aff" rid="Aff89"/></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Kyung Hee</given-names></name><address><email>ikhee@med.yu.ac.kr</email></address><xref ref-type="aff" rid="Aff90"/></contrib><contrib contrib-type="author"><name><surname>Shin</surname><given-names>Sang Joon</given-names></name><address><email>ssj338@yuhs.ac</email></address><xref ref-type="aff" rid="Aff91"/></contrib><contrib contrib-type="author"><name><surname>Kang</surname><given-names>Hye Jin</given-names></name><address><email>hyejin@kcch.re.kr</email></address><xref ref-type="aff" rid="Aff92"/></contrib><contrib contrib-type="author"><name><surname>Shin</surname><given-names>Dong Bok</given-names></name><address><email>dbs@gilhospital.com</email></address><xref ref-type="aff" rid="Aff93"/></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Jae Won</given-names></name><address><email>jael@korea.ac.kr</email></address><xref ref-type="aff" rid="Aff94"/></contrib><contrib contrib-type="author"><name><surname>Jo</surname><given-names>Sook Jung</given-names></name><address><email>jewerse@hanmail.net</email></address><xref ref-type="aff" rid="Aff95"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Park</surname><given-names>Young Suk</given-names></name><address><email>pys27hmo@skku.edu</email></address><xref ref-type="aff" rid="Aff85"/></contrib><aff id="Aff85"><label/>Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 135-710 Korea </aff><aff id="Aff86"><label/>Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea </aff><aff id="Aff87"><label/>Centre for Colorectal Cancer, National Cancer Center, Goyang, Korea </aff><aff id="Aff88"><label/>Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea </aff><aff id="Aff89"><label/>Department of Internal Medicine, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Jeollanamdo, Korea </aff><aff id="Aff90"><label/>Department of Internal Medicine, Yeungnam University Hospital, Yeungnam University College of Medicine, Daegu, Korea </aff><aff id="Aff91"><label/>Department of Internal Medicine, Cancer Metastasis Research Centre, Yonsei University College of Medicine, Seoul, Korea </aff><aff id="Aff92"><label/>Department of Internal Medicine, Korea Cancer Centre Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea </aff><aff id="Aff93"><label/>Department of Internal Medicine, Gachon University Gil Hospital, Incheon, Korea </aff><aff id="Aff94"><label/>Department of Statistics, Korea University, Seoul, Korea </aff><aff id="Aff95"><label/>Biostatistics, ICON Clinical Research, Seoul, Korea </aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>11</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>14</volume><elocation-id>883</elocation-id><history><date date-type="received"><day>27</day><month>5</month><year>2014</year></date><date date-type="accepted"><day>18</day><month>11</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; Kim et al.; licensee BioMed Central Ltd. 2014</copyright-statement><license license-type="open-access"><license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>We report updated progression-free survival (PFS) and overall survival (OS) data from a trial that compared capecitabine plus oxaliplatin (CapeOX) versus S-1 plus oxaliplatin (SOX) for the first-line treatment of metastatic colorectal cancer.</p></sec><sec><title>Methods</title><p>This trial was a randomized, two-armed, non-inferiority phase 3 comparison of CapeOX (capecitabine 1000 mg/m2 twice daily on days 1&#x02013;14 and oxaliplatin 130 mg/m2 on day 1) versus SOX (S-1 40 mg/m2 twice daily on days 1&#x02013;14 and oxaliplatin 130 mg/m2 on day 1). The primary end point was to show non-inferiority of SOX relative to CapeOX in terms of PFS. Thus, a follow-up exploratory analysis of PFS and OS was performed.</p></sec><sec><title>Results</title><p>The intention to treat (ITT) population was comprised of 340 patients (SOX arm: 168 and CapeOX arm: 172). The updated median PFS was 7.1 months (95% CI 6.4-8.0) in the SOX group and 6.3 months (95% CI 4.9-6.7) in the CapeOX group (hazard ratio [HR], 0.83 [0.66-1.04], p&#x02009;=&#x02009;.10). The median OS was 19.0 months (95% CI 15.3-23.0) in the SOX group and 18.4 months (95% CI 14.1-20.7) in the CapeOX group (HR, 0.86 [0.68-1.08], p&#x02009;=&#x02009;.19). Subgroup analyses according to principal demographic factors such as sex, age, ECOG (Eastern Cooperative Oncology Group) performance status, primary tumor location, measurability, previous adjuvant therapy, number of metastatic organs, and liver metastases showed no interaction between any of these characteristics and the treatment.</p></sec><sec><title>Conclusions</title><p>Updated survival analysis shows that SOX is similar to CapeOX, confirming the initial PFS analysis. Therefore, the SOX regimen could be an alternative first-line doublet chemotherapy strategy for patients with metastatic colorectal cancer.</p></sec><sec><title>Trial registration</title><p><ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrial.gov/ct2/show/NCT00677443?term=nct00677443&#x00026;rank=1">NCT00677443</ext-link> and May 12 2008</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Capecitabine</kwd><kwd>S-1</kwd><kwd>Colorectal cancers</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Fluoropyrimidines (5FU) have remained the most commonly prescribed agents for gastrointestinal cancer, including colorectal cancer (CRC). 5FU is administered as a continuous infusion by a portable pump or by an inserted chemo-port, methods that provide continuous exposure and modest improvement in efficacy. However, continuous infusion is inconvenient and unsafe [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Thus, the development of oral FU (capecitabine and S-1) has opened new possibilities for the treatment of gastrointestinal tumors, especially gastric cancers [<xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>]. For the first-line treatment of patients with metastatic CRC, oxaliplatin plus either fluorouracil or capecitabine has been one of the reference doublet cytotoxic chemotherapy strategies [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. S-1 is a novel oral FU consisting of a 5FU prodrug, tegafur, the dihydropyrimidine dehydrogenase inhibitor, 5-chloro-2, 4-dihydroxypyrimidine, and the orotate phosphoribosyl transferase inhibitor, potassium oxonate, which suppresses the gastrointestinal toxicity of tegafur [<xref ref-type="bibr" rid="CR8">8</xref>]. Although several trials have shown the feasibility and efficacy of S-1 plus oxaliplatin (SOX) as an upfront chemotherapy for metastatic CRC [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>], S-1 and capecitabine have not been directly compared when either is combined with oxaliplatin. To address this dearth of information, we conducted our initial randomized, non-inferiority phase III trial of SOX versus capecitabine plus oxaliplatin (CapeOX) for the first-line treatment of patients with metastatic colorectal cancer [<xref ref-type="bibr" rid="CR11">11</xref>]. We found the S-1 group to have nearly 2 months longer PFS than the capecitabine group, suggesting that the SOX regimen could be an alternative first-line doublet chemotherapy strategy for patients with metastatic CRC. However, which particular S-1s can be used as substitutes for capecitabine may be controversial in CRC. Thus, we intend to update the overall survival (OS) and progression free survival (PFS) results, and we intend to conduct exploratory analyses to determine whether the effect of S-1 on these end points appears to vary in selected patient groups.</p></sec><sec id="Sec2" sec-type="methods"><title>Methods</title><sec id="Sec3"><title>Study design</title><p>This was a randomized, open-label, multicenter phase 3 study [<xref ref-type="bibr" rid="CR11">11</xref>]. The institutional review boards of all participating institutions approved the study protocol. Written, informed consent was required for participation.</p><p>To be eligible, patients with metastatic colorectal cancer were required to have histologically confirmed adenocarcinoma, measurable or assessable lesions, an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0&#x02013;2, no previous chemotherapy or immunotherapy in a metastatic setting, adequate hematological, hepatic, and renal function, and be 18 years of age or older. Adjuvant chemotherapy or radiotherapy was permitted if it had been completed at least 6 months before enrollment. We randomly assigned eligible patients to either CapeOX or SOX in a one-to-one ratio. Randomisation was done centrally with a computer-generated sequence and a permutation block technique that ensured equal distribution of patients on the basis of primary tumor site (colon vs. rectum), history of previous adjuvant or neoadjuvant treatment, and the presence of measurable lesions.</p></sec><sec id="Sec4"><title>Procedures</title><p>All treatment cycles were administered every three weeks. We administered oral S-1 (40 mg/m2) twice a day on days 1&#x02013;14, oral capecitabine (1000 mg/m2) twice a day on days 1&#x02013;14, and oxaliplatin (130 mg/m2) on day 1 as a 2-h intravenous infusion. As many as nine cycles of oxaliplatin-containing chemotherapy were provided, except in instances of disease progression, unacceptable toxicity, or patient refusal. Maintenance chemotherapy with S-1 or capecitabine was permitted after discontinuation of oxaliplatin. Treatment responses were assessed every three cycles (9 weeks) during study treatments or sooner if needed for documentation of disease progression. Objective tumor responses were independently reviewed according to the Response Evaluation Criteria In Solid Tumors (RECIST; version 1.0).</p></sec><sec id="Sec5"><title>Statistical analyses</title><p>For the primary efficacy analysis, in which we aimed to assess the non-inferiority of SOX to CapeOX in terms of PFS (time to progression or death), we assessed all patients allocated to the treatment group (intention to treat population), and we also did a per-protocol analysis in those who received protocol treatments without major violations. PFS at 15 months in both groups was assumed to be 38%, and the low non-inferiority limit was set as &#x02212;13%, corresponding to a HR of 1.43. On the basis of these conditions, 192 events were needed for a one-sided type I error of 5% and a power of 80%. Assuming a 10% loss, we needed 344 patients. Previous reports were made at the August 31, 2011 cut-off date for data collection. These updated data were collected at the cut-off date of December 24, 2013. The survival data were assessed with the Kaplan-Meier method. We estimated the hazard ratio (HR) and corresponding 95% CI using the Cox proportional hazard regression model. Also, we analyzed post-progression survival (PPS; the duration of survival after disease progression to study medication) among two groups.</p></sec></sec><sec id="Sec6" sec-type="results"><title>Results</title><sec id="Sec7"><title>Patients</title><p>Between May 14, 2008 and September 23, 2009, we enrolled 348 patients from 11 institutions. We randomly assigned 340 patients who met the eligibility criteria to treatment (ITT). Of the 340 patients, 168 were assigned to the SOX group, and 172 were assigned to the CapeOX group (Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). This updated analysis used data collected by December 24, 2013, by which time, 301 (SOX group: 150, CapeOX group: 151) PFS events, and 279 (134; SOX group, 145; CapeOX group) OS events had occurred. In the previous analysis, 207 (98; SOX group, 109; CapeOX group) PFS events, and 179 (84; SOX group, 95; CapeOX group) OS events had occurred. Of note, the baseline characteristics were much the same between the two groups (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).<fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>CONSORT diagram.</bold>
</p></caption><graphic xlink:href="12885_2014_5129_Fig1_HTML" id="d30e579"/></fig></p><table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Baseline characteristics (intention to treat population)</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>SOX (<bold><italic>n</italic></bold>&#x02009;=&#x02009;168)</th><th>CapeOX (<bold><italic>n</italic></bold>&#x02009;=&#x02009;172)</th></tr></thead><tbody><tr><td>Primary site</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x02009;Colon</td><td align="center">109 (65%)</td><td align="center">108 (63%)</td></tr><tr><td>&#x02003;&#x02009;Rectum</td><td align="center">59 (35%)</td><td align="center">64 (37%)</td></tr><tr><td>Sex</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x02009;Male</td><td align="center">109 (65%)</td><td align="center">102 (59%)</td></tr><tr><td>&#x02003;&#x02009;Female</td><td align="center">59 (35%)</td><td align="center">70 (41%)</td></tr><tr><td>Age</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x02009;&#x02264;65 years</td><td align="center">121 (72%)</td><td align="center">126 (73%)</td></tr><tr><td>&#x02003;&#x02009;&#x0003e;65 years</td><td align="center">47 (28%)</td><td align="center">46 (27%)</td></tr><tr><td>ECOG performance status</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x02009;0-1</td><td align="center">164 (98%)</td><td align="center">168 (98%)</td></tr><tr><td>&#x02003;&#x02009;2</td><td align="center">4 (2%)</td><td align="center">4 (2%)</td></tr><tr><td>Previous (neo)adjuvant therapy</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x02009;Yes</td><td align="center">37 (22%)</td><td align="center">38 (22%)</td></tr><tr><td>&#x02003;&#x02009;No</td><td align="center">131 (78%)</td><td align="center">134 (78%)</td></tr><tr><td>Site of metastasis</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x02009;Liver metastasis</td><td align="center">105 (63%)</td><td align="center">111 (65%)</td></tr><tr><td>&#x02003;&#x02009;Non-liver metastasis</td><td align="center">63 (37%)</td><td align="center">61 (35%)</td></tr><tr><td>Number of metastatic organs</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x02009;One organ</td><td align="center">65 (39%)</td><td align="center">49 (29%)</td></tr><tr><td>&#x02003;&#x02009;Two organs</td><td align="center">61 (36%)</td><td align="center">70 (41%)</td></tr><tr><td>&#x02003;&#x02009;Three or more organs</td><td align="center">42 (25%)</td><td align="center">53 (31%)</td></tr><tr><td>Measurability</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x02009;Measurable lesions</td><td align="center">155 (92%)</td><td align="center">155 (90%)</td></tr><tr><td>&#x02003;&#x02009;Assessable lesions only</td><td align="center">13 (8%)</td><td align="center">17 (10%)</td></tr></tbody></table></table-wrap></sec><sec id="Sec8"><title>Progression-free survival (PFS) and post-progression survival (PPS)</title><p>In the SOX group with media 17.91 follow-up, the median PFS was 7.1 months (6.4-8.1), and the corresponding value in the CapeOX group with median 16.41 follow-up was 6.3 months (4.9-6.7, intention to treat [ITT] population) (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> and Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). The HR comparing PFS between the two groups was 0.83 (95% CI 0.66-1.04, <italic>p</italic>&#x02009;=&#x02009;.10). For the ITT population, the median post-progression survival (PPS) was 9.3 months in the SOX group compared to 9.5 months in the CapeOX group, with a corresponding HR of 0.97 (95% CI 0.76-1.23, <italic>p</italic>&#x02009;=&#x02009;.81) (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> and Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>
<bold>Survival outcomes</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="3">Intention to treat population</th><th colspan="3">Per-protocol population</th></tr><tr><th>SOX</th><th>CapeOX</th><th>Effect size (95% CI);
<bold><italic>p</italic></bold>
value</th><th>SOX</th><th>CapeOX</th><th>Effect size (95% CI),
<bold><italic>p</italic></bold>
value</th></tr></thead><tbody><tr><td align="center">Number of patients</td><td align="center">168</td><td align="center">172</td><td align="center"/><td align="center">164</td><td align="center">161</td><td align="center"/></tr><tr><td align="center">Median PFS</td><td align="center">7.1 (6.4-8.1)</td><td align="center">6.3 (4.9-6.7)</td><td align="center">0.83 (0.66-1.04), <italic>p</italic>&#x02009;=&#x02009;.10</td><td align="center">6.9 (6.4-7.9)</td><td align="center">6.3 (5.2-6.7)</td><td align="center">0.84 (0.67-1.06), <italic>p</italic>&#x02009;=&#x02009;.13</td></tr><tr><td align="center">Median OS</td><td align="center">19.0 (15.3-23.0)</td><td align="center">18.5 (14.1-20.8)</td><td align="center">0.86 (0.68-1.08), <italic>p</italic>&#x02009;=&#x02009;.19</td><td align="center">19.1 (15.0-23.0)</td><td align="center">17.6 (14.1-20.5)</td><td align="center">0.85 (0.67-1.08), <italic>p</italic>&#x02009;=&#x02009;.17</td></tr><tr><td align="center">Number of patients</td><td align="center">150</td><td align="center">151</td><td align="center"/><td align="center">147</td><td align="center">145</td><td align="center"/></tr><tr><td align="center">Median PPS</td><td align="center">9.3 (6.7-11.6)</td><td align="center">9.5 (7.4-12.1)</td><td align="center">0.97 (0.76-1.23), <italic>p</italic>&#x02009;=&#x02009;.81</td><td align="center">9.3 (6.9-11.6)</td><td align="center">9.6 (7.4-12.1)</td><td align="center">0.96 (0.75-1.23), <italic>p</italic>&#x02009;=&#x02009;.75</td></tr></tbody></table><table-wrap-foot><p>Data are represented as n (%), time in months (95% CI) or effect size (95% CI). SOX, S-1 plus oxaliplatin; CapeOX, Capecitabine plus oxaliplatin; PFS, progression-free survival; PPS, post-progression survival, OS&#x02009;=&#x02009;overall survival.</p></table-wrap-foot></table-wrap><fig id="Fig2"><label>Figure 2</label><caption><p>
<bold>Kaplan-Meier curves of progression-free survival (PFS) (A) and post-progression- survival (PPS) (B).</bold>
</p></caption><graphic xlink:href="12885_2014_5129_Fig2_HTML" id="d30e1041"/></fig></p></sec><sec id="Sec9"><title>Overall survival (OS)</title><p>The OS data in the ITT population as of December 24, 2013 are shown in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. The corresponding Kaplan-Meier curves for OS are shown in Figure&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>.<fig id="Fig3"><label>Figure 3</label><caption><p>
<bold>Kaplan-Meier curves of overall survival (OS).</bold>
</p></caption><graphic xlink:href="12885_2014_5129_Fig3_HTML" id="d30e1064"/></fig></p><p>For the ITT population, median OS was 19.0 months in the SOX group compared to 18.5 months in the CapeOX group, with a corresponding HR of 0.86 (95% CI 0.68-1.08).</p></sec><sec id="Sec10"><title>Subgroup analysis</title><p>OS and PFS in assigned patients were analyzed according to sex, age, ECOG PS, primary tumor site, previous adjuvant therapy, measurability, number of metastatic organs, and liver metastasis. There was no interaction between the treatment and any of these factors (Figure&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>).<fig id="Fig4"><label>Figure 4</label><caption><p>
<bold>Subgroup analysis of overall survival (A) and progression-free survival (B) for the intention to treat population.</bold>
</p></caption><graphic xlink:href="12885_2014_5129_Fig4_HTML" id="d30e1086"/></fig></p></sec></sec><sec id="Sec11" sec-type="discussion"><title>Discussion</title><p>The primary analysis of this study showed that SOX is non-inferior to CapeOX in terms of PFS, OS, and response rate as a first-line chemotherapy in patients with metastatic colorectal cancer (CRC) [<xref ref-type="bibr" rid="CR11">11</xref>]. To the best of our knowledge, this study is the first large, phase III clinical trial that directly compares SOX with CapeOX in metastatic CRC. This updated analysis also demonstrates that SOX and CapeOX have statistically similar PFS and OS, confirming the conclusion reached in our previous publication.</p><p>In this updated analysis, patients in the CapeOX group had a PFS of 6.3 months and an OS of 18.5 months, which are similar values to those reported in previous trials [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR12">12</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>]. Likewise, the SOX group in our analysis showed favorable results, which are similar to values recorded for CapeOX or FU plus oxaliplatin plus Leucovorin (FOLFOX) treatment in previous studies [<xref ref-type="bibr" rid="CR12">12</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>]. Based on our updated analysis with a long-term follow-up, no significant differences were observed in PFS and OS between the SOX and CapeOX groups, which is consistent with previous gastrointestinal cancer studies [<xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>]. In addition, a meta-analysis by Zhang et al. reported that both the S-1 and capecitabine-based regimens were equally active and well tolerated in patients with gastric cancer and CRC [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p>In this updated analysis, we also investigated the post-progression survival (PPS) for both treatment groups. In cancer treatment, the goal is to prolong survival and/or to improve the patient&#x02019;s quality of life. In the era of multiple lines of chemotherapy, therapeutic options have been expanded, especially in CRC. In breast cancer, lung cancer, and CRC, OS becomes more associated with PPS than PFS [<xref ref-type="bibr" rid="CR20">20</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>]. In CRC, the association of PPS with OS may be due to the increasing number of active compounds available, or to the available second or third-line therapies. In this analysis, there was no significant difference in PPS between the SOX and CapeOX groups (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). These findings suggest that effective treatments, equal in quality, were provided to both groups after the failure of the first-line therapy. The dose of S-1 in this study was 80 mg/m2 per day, which is higher than doses used in the reference trial that combined S-1 with oxaliplatin. As mentioned in a previously published report, this dose finding explains the high frequency of adverse events in SOX-treated patients. However, the high frequency of adverse events in the SOX group might not affect subsequent treatment strategies.</p><p>In patients with metastatic CRC, the addition of bevacizumab to the first-line chemotherapy has improved survival. Previous studies have shown that bevacizumab plus FOLFOX, FOLFIRI (leucovorin, fluorouracil, and irinotecan), or CapeOX improves PFS [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR24">24</xref>&#x02013;<xref ref-type="bibr" rid="CR26">26</xref>]. However, the role of bevacizumab with SOX has not been established. Recently, Yamada et al. showed that bevacizumab plus SOX was non-inferior to bevacizumab plus FOLFOX as a first-line treatment for metastatic CRC with respect to PFS [<xref ref-type="bibr" rid="CR27">27</xref>]. Thus, bevacizumab plus SOX might be a possible option as a standard first-line treatment, although S-1 and capecitabine have not been directly compared when either is combined with bevacizumab and oxaliplatin.</p><p>Our updated analysis confirms that a combination of S-1 and oxaliplatin can be considered as an alternative doublet chemotherapy strategy to CapeOX. Further investigation is needed to explore its potential when used together with other targeted agents or as adjuvant chemotherapy.</p></sec><sec id="Sec12" sec-type="conclusions"><title>Conclusion</title><p>Updated survival analysis shows that SOX is similar to CapeOX, confirming the initial PFS analysis. Therefore, the SOX regimen could be an alternative first-line doublet chemotherapy strategy for patients with metastatic colorectal cancer.</p><sec id="Sec13"><title>Ethics statement</title><p>The Ethics Committee at Samsung Medical Center approved the study in accordance with the Declaration of Helsinki. All individuals gave written informed consent for participation in the study.</p></sec></sec></body><back><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>Conception and design were carried out by TWK, DBS, JWL and YSP. Development of methodology was conducted by SJJ, JWL, STK, and HYL. STK, KPK, SYK, JYB, JHK, KWL, IJC, SHC, KHL, SJS, HJK and YSP participated in Acquisition of data. Analysis and interpretation of data were conducted by SJJ, STK, and JL. Writing, review and/or revision of manuscript were carried out by STK, YSH, JL, and YSP. KPK, SYK, JYB, JHK, KWL, IJC, SHC, KHL, SJS, and HJK participated in administrative, technical or material support. Study supervision was conducted by YSP. All authors read and approved the final manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This study was partly supported by a grant from the Korea Healthcare technology R&#x00026;D Project, Ministry for Health, Welfare &#x00026; Family Affairs, Republic of Korea (Grant Number.; A102065). The oxaliplatin and S-1 were provided by Jeil Pharmaceutical (Seoul, South Korea). These mentions was already revealed at previous article (Lancet Oncol 2012;13:1125). This updated-study didn&#x02019;t need additional any fund.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoffski</surname><given-names>P</given-names></name></person-group><article-title>The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors</article-title><source>Anticancer Drugs</source><year>2004</year><volume>15</volume><fpage>85</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1097/00001813-200402000-00001</pub-id><pub-id pub-id-type="pmid">15075664</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Meta-analysis Group In Cancer</collab></person-group><article-title>Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis group in cancer</article-title><source>J Clin Oncol</source><year>1998</year><volume>16</volume><fpage>301</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">9440757</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cascinu</surname><given-names>S</given-names></name></person-group><article-title>Oral treatment for gastric cancer: new choices, better choices?</article-title><source>Lancet Oncol</source><year>2008</year><volume>9</volume><fpage>188</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(08)70042-1</pub-id><pub-id pub-id-type="pmid">18308239</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cervantes</surname><given-names>A</given-names></name><name><surname>Roda</surname><given-names>D</given-names></name><name><surname>Tarazona</surname><given-names>N</given-names></name><name><surname>Rosello</surname><given-names>S</given-names></name><name><surname>Perez-Fidalgo</surname><given-names>JA</given-names></name></person-group><article-title>Current questions for the treatment of advanced gastric cancer</article-title><source>Cancer Treat Rev</source><year>2013</year><volume>39</volume><fpage>60</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2012.09.007</pub-id><pub-id pub-id-type="pmid">23102520</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pieters</surname><given-names>A</given-names></name><name><surname>Laurent</surname><given-names>S</given-names></name><name><surname>Dero</surname><given-names>I</given-names></name><name><surname>Van Damme</surname><given-names>N</given-names></name><name><surname>Peeters</surname><given-names>M</given-names></name></person-group><article-title>The role of oral fluoropyrimidines in the treatment of advanced gastric cancer</article-title><source>Acta Gastroenterol Belg</source><year>2008</year><volume>71</volume><fpage>361</fpage><lpage>366</lpage><pub-id pub-id-type="pmid">19317275</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cassidy</surname><given-names>J</given-names></name><name><surname>Tabernero</surname><given-names>J</given-names></name><name><surname>Twelves</surname><given-names>C</given-names></name><name><surname>Brunet</surname><given-names>R</given-names></name><name><surname>Butts</surname><given-names>C</given-names></name><name><surname>Conroy</surname><given-names>T</given-names></name><name><surname>Debraud</surname><given-names>F</given-names></name><name><surname>Figer</surname><given-names>A</given-names></name><name><surname>Grossmann</surname><given-names>J</given-names></name><name><surname>Sawada</surname><given-names>N</given-names></name><name><surname>Schoffski</surname><given-names>P</given-names></name><name><surname>Sobrero</surname><given-names>A</given-names></name><name><surname>Van Cutsem</surname><given-names>E</given-names></name><name><surname>Diaz-Rubio</surname><given-names>E</given-names></name></person-group><article-title>XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><fpage>2084</fpage><lpage>2091</lpage><pub-id pub-id-type="doi">10.1200/JCO.2004.11.069</pub-id><pub-id pub-id-type="pmid">15169795</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Gramont</surname><given-names>A</given-names></name><name><surname>Figer</surname><given-names>A</given-names></name><name><surname>Seymour</surname><given-names>M</given-names></name><name><surname>Homerin</surname><given-names>M</given-names></name><name><surname>Hmissi</surname><given-names>A</given-names></name><name><surname>Cassidy</surname><given-names>J</given-names></name><name><surname>Boni</surname><given-names>C</given-names></name><name><surname>Cortes-Funes</surname><given-names>H</given-names></name><name><surname>Cervantes</surname><given-names>A</given-names></name><name><surname>Freyer</surname><given-names>G</given-names></name><name><surname>Papamichael</surname><given-names>D</given-names></name><name><surname>Le Bail</surname><given-names>N</given-names></name><name><surname>Louvet</surname><given-names>C</given-names></name><name><surname>Hendler</surname><given-names>D</given-names></name><name><surname>de Braud</surname><given-names>F</given-names></name><name><surname>Wilson</surname><given-names>C</given-names></name><name><surname>Morvan</surname><given-names>F</given-names></name><name><surname>Bonetti</surname><given-names>A</given-names></name></person-group><article-title>Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer</article-title><source>J Clin Oncol</source><year>2000</year><volume>18</volume><fpage>2938</fpage><lpage>2947</lpage><pub-id pub-id-type="pmid">10944126</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maehara</surname><given-names>Y</given-names></name></person-group><article-title>S-1 in gastric cancer: a comprehensive review</article-title><source>Gastric Cancer</source><year>2003</year><volume>6</volume><issue>Suppl 1</issue><fpage>2</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1007/s10120-003-0232-9</pub-id><pub-id pub-id-type="pmid">12775012</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>Y</given-names></name><name><surname>Tahara</surname><given-names>M</given-names></name><name><surname>Miya</surname><given-names>T</given-names></name><name><surname>Satoh</surname><given-names>T</given-names></name><name><surname>Shirao</surname><given-names>K</given-names></name><name><surname>Shimada</surname><given-names>Y</given-names></name><name><surname>Ohtsu</surname><given-names>A</given-names></name><name><surname>Sasaki</surname><given-names>Y</given-names></name><name><surname>Tanigawara</surname><given-names>Y</given-names></name></person-group><article-title>Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer</article-title><source>Br J Cancer</source><year>2008</year><volume>98</volume><fpage>1034</fpage><lpage>1038</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6604271</pub-id><pub-id pub-id-type="pmid">18319719</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zang</surname><given-names>DY</given-names></name><name><surname>Lee</surname><given-names>BH</given-names></name><name><surname>Park</surname><given-names>HC</given-names></name><name><surname>Song</surname><given-names>HH</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Jung</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>HY</given-names></name><name><surname>Kwon</surname><given-names>JH</given-names></name><name><surname>Hwang</surname><given-names>SW</given-names></name><name><surname>Park</surname><given-names>SR</given-names></name><name><surname>Park</surname><given-names>CH</given-names></name><name><surname>Kim</surname><given-names>KO</given-names></name><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Jang</surname><given-names>KM</given-names></name></person-group><article-title>Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer</article-title><source>Ann Oncol</source><year>2009</year><volume>20</volume><fpage>892</fpage><lpage>896</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdn721</pub-id><pub-id pub-id-type="pmid">19153122</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>YS</given-names></name><name><surname>Park</surname><given-names>YS</given-names></name><name><surname>Lim</surname><given-names>HY</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>TW</given-names></name><name><surname>Kim</surname><given-names>KP</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Baek</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>KW</given-names></name><name><surname>Chung</surname><given-names>IJ</given-names></name><name><surname>Cho</surname><given-names>SH</given-names></name><name><surname>Lee</surname><given-names>KH</given-names></name><name><surname>Shin</surname><given-names>SJ</given-names></name><name><surname>Kang</surname><given-names>HJ</given-names></name><name><surname>Shin</surname><given-names>DB</given-names></name><name><surname>Jo</surname><given-names>SJ</given-names></name><name><surname>Lee</surname><given-names>JW</given-names></name></person-group><article-title>S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial</article-title><source>Lancet Oncol</source><year>2012</year><volume>13</volume><fpage>1125</fpage><lpage>1132</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(12)70363-7</pub-id><pub-id pub-id-type="pmid">23062232</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cassidy</surname><given-names>J</given-names></name><name><surname>Clarke</surname><given-names>S</given-names></name><name><surname>Diaz-Rubio</surname><given-names>E</given-names></name><name><surname>Scheithauer</surname><given-names>W</given-names></name><name><surname>Figer</surname><given-names>A</given-names></name><name><surname>Wong</surname><given-names>R</given-names></name><name><surname>Koski</surname><given-names>S</given-names></name><name><surname>Rittweger</surname><given-names>K</given-names></name><name><surname>Gilberg</surname><given-names>F</given-names></name><name><surname>Saltz</surname><given-names>L</given-names></name></person-group><article-title>XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results</article-title><source>Br J Cancer</source><year>2011</year><volume>105</volume><fpage>58</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1038/bjc.2011.201</pub-id><pub-id pub-id-type="pmid">21673685</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rothenberg</surname><given-names>ML</given-names></name><name><surname>Cox</surname><given-names>JV</given-names></name><name><surname>Butts</surname><given-names>C</given-names></name><name><surname>Navarro</surname><given-names>M</given-names></name><name><surname>Bang</surname><given-names>YJ</given-names></name><name><surname>Goel</surname><given-names>R</given-names></name><name><surname>Gollins</surname><given-names>S</given-names></name><name><surname>Siu</surname><given-names>LL</given-names></name><name><surname>Laguerre</surname><given-names>S</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name></person-group><article-title>Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study</article-title><source>Ann Oncol</source><year>2008</year><volume>19</volume><fpage>1720</fpage><lpage>1726</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdn370</pub-id><pub-id pub-id-type="pmid">18550577</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saltz</surname><given-names>LB</given-names></name><name><surname>Clarke</surname><given-names>S</given-names></name><name><surname>Diaz-Rubio</surname><given-names>E</given-names></name><name><surname>Scheithauer</surname><given-names>W</given-names></name><name><surname>Figer</surname><given-names>A</given-names></name><name><surname>Wong</surname><given-names>R</given-names></name><name><surname>Koski</surname><given-names>S</given-names></name><name><surname>Lichinitser</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>TS</given-names></name><name><surname>Rivera</surname><given-names>F</given-names></name><name><surname>Couture</surname><given-names>F</given-names></name><name><surname>Sirzen</surname><given-names>F</given-names></name><name><surname>Cassidy</surname><given-names>J</given-names></name></person-group><article-title>Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>2013</fpage><lpage>2019</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.14.9930</pub-id><pub-id pub-id-type="pmid">18421054</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JL</given-names></name><name><surname>Kang</surname><given-names>YK</given-names></name><name><surname>Kang</surname><given-names>HJ</given-names></name><name><surname>Lee</surname><given-names>KH</given-names></name><name><surname>Zang</surname><given-names>DY</given-names></name><name><surname>Ryoo</surname><given-names>BY</given-names></name><name><surname>Kim</surname><given-names>JG</given-names></name><name><surname>Park</surname><given-names>SR</given-names></name><name><surname>Kang</surname><given-names>WK</given-names></name><name><surname>Shin</surname><given-names>DB</given-names></name><name><surname>Ryu</surname><given-names>MH</given-names></name><name><surname>Chang</surname><given-names>HM</given-names></name><name><surname>Kim</surname><given-names>TW</given-names></name><name><surname>Baek</surname><given-names>JH</given-names></name><name><surname>Min</surname><given-names>YJ</given-names></name></person-group><article-title>A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer</article-title><source>Br J Cancer</source><year>2008</year><volume>99</volume><fpage>584</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6604536</pub-id><pub-id pub-id-type="pmid">18665164</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>GM</given-names></name><name><surname>Jeung</surname><given-names>HC</given-names></name><name><surname>Rha</surname><given-names>SY</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Jung</surname><given-names>I</given-names></name><name><surname>Nam</surname><given-names>BH</given-names></name><name><surname>Lee</surname><given-names>KH</given-names></name><name><surname>Chung</surname><given-names>HC</given-names></name></person-group><article-title>A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer</article-title><source>Eur J Cancer</source><year>2012</year><volume>48</volume><fpage>518</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2011.12.017</pub-id><pub-id pub-id-type="pmid">22243774</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seol</surname><given-names>YM</given-names></name><name><surname>Song</surname><given-names>MK</given-names></name><name><surname>Choi</surname><given-names>YJ</given-names></name><name><surname>Kim</surname><given-names>GH</given-names></name><name><surname>Shin</surname><given-names>HJ</given-names></name><name><surname>Song</surname><given-names>GA</given-names></name><name><surname>Chung</surname><given-names>JS</given-names></name><name><surname>Cho</surname><given-names>GJ</given-names></name></person-group><article-title>Oral fluoropyrimidines (capecitabine or S-1) and cisplatin as first line treatment in elderly patients with advanced gastric cancer: a retrospective study</article-title><source>Jpn J Clin Oncol</source><year>2009</year><volume>39</volume><fpage>43</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1093/jjco/hyn119</pub-id><pub-id pub-id-type="pmid">18997184</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shitara</surname><given-names>K</given-names></name><name><surname>Sawaki</surname><given-names>A</given-names></name><name><surname>Matsuo</surname><given-names>K</given-names></name><name><surname>Kondo</surname><given-names>C</given-names></name><name><surname>Takahari</surname><given-names>D</given-names></name><name><surname>Ura</surname><given-names>T</given-names></name><name><surname>Tajika</surname><given-names>M</given-names></name><name><surname>Niwa</surname><given-names>Y</given-names></name><name><surname>Muro</surname><given-names>K</given-names></name></person-group><article-title>A retrospective comparison of S-1 plus cisplatin and capecitabine plus cisplatin for patients with advanced or recurrent gastric cancer</article-title><source>Int J Clin Oncol</source><year>2013</year><volume>18</volume><fpage>539</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1007/s10147-012-0416-6</pub-id><pub-id pub-id-type="pmid">22552360</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Cao</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Gu</surname><given-names>D</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>C</given-names></name></person-group><article-title>Comparison of the efficacy and safety of S-1-based and capecitabine-based regimens in gastrointestinal cancer: a meta-analysis</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><fpage>e84230</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0084230</pub-id><pub-id pub-id-type="pmid">24392116</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrelli</surname><given-names>F</given-names></name><name><surname>Barni</surname><given-names>S</given-names></name></person-group><article-title>Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer</article-title><source>Ann Oncol</source><year>2013</year><volume>24</volume><fpage>186</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1093/annonc/mds289</pub-id><pub-id pub-id-type="pmid">22898038</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zietemann</surname><given-names>VD</given-names></name><name><surname>Schuster</surname><given-names>T</given-names></name><name><surname>Duell</surname><given-names>TH</given-names></name></person-group><article-title>Post-study therapy as a source of confounding in survival analysis of first-line studies in patients with advanced non-small-cell lung cancer</article-title><source>J Thorac Dis</source><year>2011</year><volume>3</volume><fpage>88</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">22263071</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hotta</surname><given-names>K</given-names></name><name><surname>Kiura</surname><given-names>K</given-names></name><name><surname>Fujiwara</surname><given-names>Y</given-names></name><name><surname>Takigawa</surname><given-names>N</given-names></name><name><surname>Hisamoto</surname><given-names>A</given-names></name><name><surname>Ichihara</surname><given-names>E</given-names></name><name><surname>Tabata</surname><given-names>M</given-names></name><name><surname>Tanimoto</surname><given-names>M</given-names></name></person-group><article-title>Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><fpage>e26646</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0026646</pub-id><pub-id pub-id-type="pmid">22114662</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broglio</surname><given-names>KR</given-names></name><name><surname>Berry</surname><given-names>DA</given-names></name></person-group><article-title>Detecting an overall survival benefit that is derived from progression-free survival</article-title><source>J Natl Cancer Inst</source><year>2009</year><volume>101</volume><fpage>1642</fpage><lpage>1649</lpage><pub-id pub-id-type="doi">10.1093/jnci/djp369</pub-id><pub-id pub-id-type="pmid">19903805</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cassidy</surname><given-names>J</given-names></name><name><surname>Clarke</surname><given-names>S</given-names></name><name><surname>Diaz-Rubio</surname><given-names>E</given-names></name><name><surname>Scheithauer</surname><given-names>W</given-names></name><name><surname>Figer</surname><given-names>A</given-names></name><name><surname>Wong</surname><given-names>R</given-names></name><name><surname>Koski</surname><given-names>S</given-names></name><name><surname>Lichinitser</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>TS</given-names></name><name><surname>Rivera</surname><given-names>F</given-names></name><name><surname>Couture</surname><given-names>F</given-names></name><name><surname>Sirzen</surname><given-names>F</given-names></name><name><surname>Saltz</surname><given-names>L</given-names></name></person-group><article-title>Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>2006</fpage><lpage>2012</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.14.9898</pub-id><pub-id pub-id-type="pmid">18421053</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>RM</given-names></name><name><surname>Sargent</surname><given-names>DJ</given-names></name><name><surname>Morton</surname><given-names>RF</given-names></name><name><surname>Fuchs</surname><given-names>CS</given-names></name><name><surname>Ramanathan</surname><given-names>RK</given-names></name><name><surname>Williamson</surname><given-names>SK</given-names></name><name><surname>Findlay</surname><given-names>BP</given-names></name><name><surname>Pitot</surname><given-names>HC</given-names></name><name><surname>Alberts</surname><given-names>SR</given-names></name></person-group><article-title>A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><fpage>23</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1200/JCO.2004.09.046</pub-id><pub-id pub-id-type="pmid">14665611</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tournigand</surname><given-names>C</given-names></name><name><surname>Andre</surname><given-names>T</given-names></name><name><surname>Achille</surname><given-names>E</given-names></name><name><surname>Lledo</surname><given-names>G</given-names></name><name><surname>Flesh</surname><given-names>M</given-names></name><name><surname>Mery-Mignard</surname><given-names>D</given-names></name><name><surname>Quinaux</surname><given-names>E</given-names></name><name><surname>Couteau</surname><given-names>C</given-names></name><name><surname>Buyse</surname><given-names>M</given-names></name><name><surname>Ganem</surname><given-names>G</given-names></name><name><surname>Landi</surname><given-names>B</given-names></name><name><surname>Colin</surname><given-names>P</given-names></name><name><surname>Louvet</surname><given-names>C</given-names></name><name><surname>de Gramont</surname><given-names>A</given-names></name></person-group><article-title>FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><fpage>229</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1200/JCO.2004.05.113</pub-id><pub-id pub-id-type="pmid">14657227</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>Y</given-names></name><name><surname>Takahari</surname><given-names>D</given-names></name><name><surname>Matsumoto</surname><given-names>H</given-names></name><name><surname>Baba</surname><given-names>H</given-names></name><name><surname>Nakamura</surname><given-names>M</given-names></name><name><surname>Yoshida</surname><given-names>K</given-names></name><name><surname>Yoshida</surname><given-names>M</given-names></name><name><surname>Iwamoto</surname><given-names>S</given-names></name><name><surname>Shimada</surname><given-names>K</given-names></name><name><surname>Komatsu</surname><given-names>Y</given-names></name><name><surname>Sasaki</surname><given-names>Y</given-names></name><name><surname>Satoh</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Mishima</surname><given-names>H</given-names></name><name><surname>Muro</surname><given-names>K</given-names></name><name><surname>Watanabe</surname><given-names>M</given-names></name><name><surname>Sakata</surname><given-names>Y</given-names></name><name><surname>Morita</surname><given-names>S</given-names></name><name><surname>Shimada</surname><given-names>Y</given-names></name><name><surname>Sugihara</surname><given-names>K</given-names></name></person-group><article-title>Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial</article-title><source>Lancet Oncol</source><year>2013</year><volume>14</volume><fpage>1278</fpage><lpage>1286</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(13)70490-X</pub-id><pub-id pub-id-type="pmid">24225157</pub-id></element-citation></ref><ref-list id="BSec1"><title>Pre-publication history</title><ref id="CR28"><mixed-citation publication-type="other">The pre-publication history for this paper can be accessed here:
<ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/14/883/prepub">http://www.biomedcentral.com/1471-2407/14/883/prepub</ext-link></mixed-citation></ref></ref-list></ref-list></back></article>